GABA receptor Inhibitors
4 drugsAbout GABA receptor
The GABA receptor is the primary inhibitory neurotransmitter receptor in the central nervous system (CNS), mediating the effects of gamma-aminobutyric acid (GABA) to decrease neuronal excitability. Its activation leads to reduced brain activity, playing a crucial role in neuronal signaling and maintaining brain homeostasis.
Human genetic studies provide strong validation for GABRA1 (max score 0.91) as a therapeutic target, with variants linked to developmental and epileptic encephalopathy, juvenile myoclonic epilepsy and childhood absence epilepsy. Loss-of-function variants are associated with increased disease risk, suggesting activation of GABA receptor may be beneficial.
GABA receptors are targeted by 3 FDA-approved small molecule drugs including FELBAMATE, ESZOPICLONE, and LUNESTA, primarily for CNS disorders. These drugs are marketed by ANI PHARMS, Sun Pharma and WAYLIS THERAP, spanning indications beyond the CNS.
GABA receptor Genetic Evidence Strong
GABRA1 has strong genetic support (score 0.91) linking it to 13 diseases, including multiple forms of epilepsy.
Strong genetic support increases confidence in target validation and likelihood of clinical success.
💡 Why activation?
- • Loss-of-function variants increase disease risk (OR > 1) — restoring function may help
- • 100% directional consistency across 3 traits
- • Strong signal in nervous system disease, genetic, familial or congenital disease pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
13 totalGWAS and other genetic studies link GABRA1 to 13 diseases.
Loss-of-function causes disease; activation may help
Loss-of-function causes disease; activation may help
🔗 Colocalization Evidence 3 strong
max H4: 0.97eQTL/pQTL signals for GABRA1 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top GABA receptor Drugs
The GABA receptor market is concentrated among 3 companies: ANI PHARMS, Sun Pharma, and WAYLIS THERAP.
The limited number of players suggests potential for new entrants with differentiated GABA receptor modulators.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| ESZOPICLONE | MACLEODS PHARMS | 2011 | 1 |
GABA receptor Drug Modality Landscape
Modalities
Routes of Administration
GABA receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like biologics could offer a competitive advantage in modulating GABA receptor activity.
GABA receptor Clinical Trials 47 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on GABA receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 10 | 7 | 2 | 1 | 78% |
| Phase 2 | 15 | 9 | 2 | 4 | 82% |
| Phase 3 | 8 | 6 | 0 | 2 | 100% |
| Phase 4 | 14 | 12 | 0 | 2 | 100% |
Top Sponsors
By Modality
GABA receptor Drug Approval Timeline (2004 - 2012)
The first GABA receptor drug was approved in 2004 (LUNESTA), with the most recent approval in 2011 (ESZOPICLONE).
The relatively long gap since the last approval indicates a potential opportunity for innovative GABA receptor-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 4 companies competing
- • Market share by company
Full Drug Portfolio
- • All 4 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 4-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 37 (9 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on GABA receptor. A trial counts if an approved drug acting on GABA receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.